|Articles|October 7, 2021
Supplements and Featured Publications
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Advertisement
This publication was funded and developed by United Therapeutics.
This AJMC® Clinical Brief summarizes results of the pivotal study by Aaron Waxman MD, PhD, et al published in The New England Journal of Medicine on the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
2
Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen
3
Stronger Carer-Child Bonds Don’t Predict Later Mental Health
4
FDA to Remove Black Box Warnings From HRT, Debate Ensues
5












































